Evaluating Buspirone to Treat Opioid Withdrawal
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise taper. During this 10 to 12-day residential study, participants with OUD will be enrolled, stabilized on a short-acting opioid, undergo an opioid stepwise taper, and complete a post-taper observation period where participants will have the opportunity to initiate long-term buprenorphine or extended-release naltrexone.
Sponsor: University of Maryland, Baltimore
You may qualify if…
- ✓ Aged 18-75
- ✓ Opioid positive urine sample
- ✓ Current moderate-severe opioid use disorder with evidence of physical dependence
- ✓ Interested in undergoing opioid detoxification
You may not qualify if…
- ✕ Being pregnant or breastfeeding
- ✕ Enrolled in methadone or buprenorphine maintenance treatment
- ✕ Allergic to study medication or taking medications that are contraindicated with study medication (e.g., CYP3A4 inhibitors or inducers and/or monoamine oxidase (MAO) inhibitors)
- ✕ Significant mental health or physical disorder, or life circumstance, that is expected to interfere with study participation (detailed further in protection of human subjects form).
- ✕ Hypotension and/or prolonged QTc interval
Where it's recruiting
Baltimore
Source: ClinicalTrials.gov · NCT05511909 · last updated 2026-05-01